Genetic analysis should be included in clinical practice when screening for antithrombin deficiency

Thrombosis and Haemostasis

Volumn 113, Issue 2, 2015, Pages 262-271

  Zeng, Wei ^a,b   Tang, Liang ^a,b   Jian, Xiao Rong ^c   Li, Yi Qing ^a   Guo, Tao ^a,b   Wang, Qing Yun ^a,b   Liu, Hui ^a,b   Wu, Ying Ying ^a,b   Cheng, Zhi Peng ^a,b   Hu, Bei ^a,b   Lu, Xuan ^a,b   Yu, Jian Ming ^a,b   Deng, Jun ^a,b   Wang, Hua Fang ^a,b   Sun, Chun Yan ^a,b   Yang, Yan ^a,b   Hu, Yu ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Hubei Clinical and Research Center of Thrombosis and Hemostasis   (China)

^c CENTRAL HOSPITAL OF WUHAN   (China)

Author keywords

Activity assay; Antithrombin deficiency; Genetic; Mutation; Thrombosis

Indexed keywords

ANTITHROMBIN III; RECOMBINANT PROTEIN; SERPINC1 PROTEIN, HUMAN;

ADULT; AGE; AGED; ANTITHROMBIN DEFICIENCY; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MISSENSE MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SERPINC1 GENE; THROMBIN TIME; VEIN THROMBOSIS; WESTERN BLOTTING; YOUNG ADULT; ANTITHROMBIN III DEFICIENCY; BLOOD CLOTTING TEST; FLUORESCENCE MICROSCOPY; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HEK293 CELL LINE; MUTATION; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PEDIGREE; PROTEIN SECONDARY STRUCTURE; RISK FACTOR; THROMBOSIS; VENOUS THROMBOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTITHROMBIN III; ANTITHROMBIN III DEFICIENCY; BLOOD COAGULATION TESTS; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEK293 CELLS; HUMANS; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; MUTATION; PEDIGREE; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; RISK FACTORS; THROMBOSIS; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 84922424377     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-05-0446     Document Type: Article

References (37)

1. Perry DJ, Carrell RW. Molecular genetics of human antithrombin deficiency. Human Mutation 1996; 7: 7-22.
2. Stevic I, Chan HH, Chander A, et al. Covalently linking heparin to antithrombin enhances prothrombinase inhibition on activated platelets. Thromb Haemost 2013; 109: 1016-1024.
3. Yang L, Manithody C, Qureshi SH, et al. Contribution of exosite occupancy by heparin to the regulation of coagulation proteases by antithrombin. Thromb Haemost 2010; 103: 277-283.
4. Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia 2008; 14: 1229-1239.
5. Bock SC, Wion KL, Vehar GA, et al. Cloning and expression of the cDNA for human antithrombin III. Nucleic Acids Res 1982; 10: 8113-8125.
6. Zhu T, Ding Q, Bai X, et al. Normal ranges and genetic variants of antithrombin, protein C and protein S in the general Chinese population. Results of the Chinese Hemostasis Investigation on Natural Anticoagulants Study I Group. Haematologica 2011; 96: 1033-1040.
7. Kim HJ, Seo JY, Lee KO, et al. Distinct frequencies and mutation spectrums of genetic thrombophilia in Korea in comparison with other Asian countries both in patients with thromboembolism and in the general population. Haematologica 2014; 99: 561-569.
8. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106-112.
9. van Boven HH, Vandenbroucke JP, Briet E, et al. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency. Blood 1999; 94: 2590-2594.
10. Luxembourg B, Pavlova A, Geisen C, et al. Impact of the type of SERPINC1 mutation and subtype of antithrombin deficiency on the thrombotic phenotype in hereditary antithrombin deficiency. Thromb Haemost 2014; 111: 249-257.
11. Khor B, Van Cott EM. Laboratory tests for antithrombin deficiency. Am J Hematol 2010; 85: 947-950.
12. Castaldo G, Cerbone AM, Guida A, et al. Molecular analysis and genotype-phenotype correlation in patients with antithrombin deficiency from Southern Italy. Thromb Haemost 2012; 107: 673-680.
13. Luxembourg B, Delev D, Geisen C, et al. Molecular basis of antithrombin deficiency. Thromb Haemost 2011; 105: 635-646.
14. Di Perna P, Vecchione G, D'Andrea G, et al. Identification of six novel mutations in type I antithrombin deficient Italian families. Haematologica 2004; 89: 117-118.
15. Fischer R, Sachs UJ, Heidinger KS, et al. Prevalence of hereditary antithrombin mutations is higher than estimated in patients with thrombotic events. Blood Coagul Fibrinol 2013; 24: 444-448.
16. Tang L, Guo T, Yang R, et al. Genetic background analysis of protein C deficiency demonstrates a recurrent mutation associated with venous thrombosis in Chinese population. PLoS One 2012; 7: e35773.
17. Tang L, Wang HF, Lu X, et al. Common genetic risk factors for venous thrombosis in the Chinese population. American journal of human genetics 2013; 92: 177-187.
18. Picard V, Chen JM, Tardy B, et al. Detection and characterisation of large SERPINC1 deletions in type I inherited antithrombin deficiency. Human Genetics 2010; 127: 45-53.
19. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nature Methods 2010; 7: 248-249.
20. Schwarz JM, Rodelsperger C, Schuelke M, et al. MutationTaster evaluates disease-causing potential of sequence alterations. Nature Methods 2010; 7: 575-576.
21. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4: 1073-1081.
22. McCoy AJ, Pei XY, Skinner R, et al. Structure of beta-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity. J Mol Biol 2003; 326: 823-833.
23. Kurihara M, Watanabe K, Inoue S, et al. Characterization of two novel mutations of the antithrombin gene observed in Japanese thrombophilic patients. Thromb Res 2005; 115: 351-358.
24. Tang L, Jian XR, Hamasaki N, et al. Molecular basis of protein S deficiency in China. Am J Hematol 2013; 88: 899-905.
25. Mitsuguro M, Sakata T, Okamoto A, et al. Usefulness of antithrombin deficiency phenotypes for risk assessment of venous thromboembolism: type I deficiency as a strong risk factor for venous thromboembolism. Intern J Hematol 2010; 92: 468-473.
26. Corral J, Hernandez-Espinosa D, Soria JM, et al. Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood 2007; 109: 4258-4263.
27. Roldan V, Ordonez A, Marin F, et al. Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. Thromb Haemost 2009; 101: 483-486.
28. Perry DJ, Daly ME, Tait RC, et al. Antithrombin cambridge II (Ala384Ser): clinical, functional and haplotype analysis of 18 families. Thromb Haemost 1998; 79: 249-253.
29. Chang JY, Tran TH. Antithrombin III Basel. Identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity. J Biol Chem 1986; 261: 1174-1176.
30. Puurunen M, Salo P, Engelbarth S, et al. Type II antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population: clinical picture. J Thromb Haemost 2013; 11: 1844-1849.
31. Daly M, Bruce D, Perry DJ, et al. Antithrombin Dublin (-3 Val-Glu): an N-terminal variant which has an aberrant signal peptidase cleavage site. FEBS letters 1990; 273: 87-90.
32. Ungerstedt JS, Schulman S, Egberg N, et al. Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: do factor Xa-based methods overestimate antithrombin activity in some patients? Blood 2002; 99: 2271-2272.
33. Javela K, Engelbarth S, Hiltunen L, et al. Great discrepancy in antithrombin activity measured using five commercially available functional assays. Thromb Res 2013; 132: 132-137.
34. Cooper PC, Coath F, Daly ME, et al. The phenotypic and genetic assessment of antithrombin deficiency. Intern J Lab Hematol 2011; 33: 227-237.
35. Kristensen SR, Rasmussen B, Pedersen S, et al. Detecting antithrombin deficiency may be a difficult task-more than one test is necessary. J Thromb Haemost 2007; 5: 617-618.
36. Caspers M, Pavlova A, Driesen J, et al. Deficiencies of antithrombin, protein C and protein S-practical experience in genetic analysis of a large patient cohort. Thromb Haemost 2012; 108: 247-257.
37. Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006; 10: 1-110.